Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience

详细信息    查看全文

• 作者：Herpreet Deol ; Leoni Lekkakou ; Ananth K. Viswanath ; Joseph M. Pappachan
• 关键词：Diabesity ; Glucagon ; like peptide ; 1 (GLP ; 1) agonist ; Sodium ; glucose co ; transporter type ; 2 (SGLT ; 2) inhibitors ; Management of diabesity ; Anti ; diabetic combination regimen
• 刊名：Endocrine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：55
• 期：1
• 页码：173-178
• 全文大小：
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, Humanities and Social Sciences, multidisciplinary;
• 出版者：Springer US
• ISSN：1559-0100
• 卷排序：55

文摘

Diabesity—obesity resulting in diabetes—is a major health problem globally because of the obesity epidemic. Several anti-diabetic medications cause weight gain and may worsen obesity, and possibly diabeisty. Two recent small retrospective cohort studies showed weight loss and diabetes improvement with combination of glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose co-transporter type-2 (SGLT-2) inhibitors in obese subjects. We assessed the effect of combination therapy with GLP-1 agonists and SGLT-2 inhibitors in the management of diabesity in a retrospective study at the Wolverhampton Diabetes Centre. Out of 79 patients on this combination regimen with other anti-diabetic medications, 37 cases who had follow up at 3–6 months were studied. Mean age and duration of follow up were 57.4 (+/−7.8) and 139 (+/−32.6) days, respectively. Twenty-two patients (59.5 %) were Asians. Statistically significant improvements in clinical parameters such as body weight reduction (3.07 kg), glycated haemoglobin (HbA1c) reduction (1.05 %), lower BMI (−1.13 kg/M2) and insulin dose reduction (6.8 units) were observed (p < 0.05 for all) in patients on combination regimen. Linear regression analysis showed that baseline HbA1c and baseline insulin dose were independent predictors of HbA1c reduction and insulin dose reduction, respectively. Our results suggest that combination therapy with GLP-1 agonists and SGLT-2 inhibitors is a promising option for patients with diabesity.